Thermo Fisher Scientific Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.7%projected annual EPS growth
Analyst Coverage
26analysts covering
FY Revenue (est.)
$47.9Bnext fiscal year
FY EPS (est.)
$25.12next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
| Q4 2026 Earnings Release | 28 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth Quarterly5.0%
Adjusted Operating Margin Quarterly22.8%Target: 22.7% - 22.8%
Adjusted Earnings Per Share (EPS) Quarterly6.0Target: 24.93 - 25.33
Watch Items
- Pharma and Biotech End-Market RecoveryTrigger: Organic growth stepping up to ~4% in H2 2026Action: Monitor quarterly segment revenues, particularly Laboratory Products and Biopharma Services, to confirm sustained customer activity.
- Clario Acquisition IntegrationTrigger: Expected full-year adjusted EPS contribution of $0.32Action: Track synergy capture, integration costs, and accretion metrics in upcoming quarterly reports.
- Academic and Government Funding VolatilityTrigger: Prolonged stagnation or cuts in NIH/government research budgetsAction: Assess management commentary on academic end-market demand and adjust full-year organic growth expectations if funding fails to stabilize.
Research as of 2 Sep 2026